Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Liposomal irinotecan · Camptosar, Onivyde

Antibody-drug conjugate · Inhibitor of DNA topoisomerase I (TOP1) · developed by Pfizer

Approved FDA, Jun 1996
1 Registered trials

What is Liposomal irinotecan?

Liposomal irinotecan is a liposomal formulation of irinotecan, a camptothecin derivative that binds the topoisomerase I-DNA complex and prevents religation of DNA single-strand breaks, leading to double-strand DNA damage. It is used in the treatment of pancreatic ductal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Camptosar, Onivyde
Drug type
Antibody-drug conjugate
Targets
DNA topoisomerase I (TOP1)
Mechanism
Inhibitor of DNA topoisomerase I (TOP1)
Pathways
DNA replication-associated double-strand breaks
Therapy area
Oncology
Developer
Pfizer Inc
In trials of
RVMD
FDA status
Approved as Camptosar, Onivyde (June 14, 1996), NDA020571 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06625320 Phase 3 Pancreatic Cancer Active not recruiting RVMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma

Other drugs acting on TOP1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.